【摘要】 目的:探讨膀胱癌术后吡柔比星(THP)膀胱灌注预防复发的临床疗效。方法:将90例浅表性膀胱癌术后患者随机分为A、B、C 3组,每组30例,其中A组行膀胱灌注吡柔比星治疗,30 mg/次,1次/周,共治疗8次。B组也行膀胱灌注吡柔比星治疗,且前8周治疗与A组相同,之后改为每月灌注1次,30 mg/次,连用10个月,总周期12个月。C组行膀胱灌注卡介苗(BCG)治疗,80 mg/次,1次/周,以后逐渐减少治疗次数,总周期12个月。比较3组患者的不良反应以及复发率。结果:3组患者均随访2年,其中A、B、C 3组患者1年后的复发率分别为10.0%(3/30)、6.7%(2/30)和6.7%(2/30),差异无统计学意义(χ2=1.8,P>0.05)。3组患者2年后的复发率分别为16.7%(5/30)、13.3%(4/30)和9.0%(3/30),其中A组与C组差异有统计学意义(χ2=9.2,P<0.05)。3组不良反应发生率分别为10.0%(3/30)、20.0%(6/30)和36.7%(11/30),A、B两组的不良反应少于C组(χ2=11.8,P<0.05)。结论:THP用于膀胱灌注预防膀胱癌术后复发,短期与长期疗效相比无统计学差异,且长期疗效与BCG疗效相比无统计学差异,但不良反应较少,可根据患者的具体情况用药。更多还原

【Abstract】 OBJECTIVE:To investigate clinical efficacy of pirarubicin(THP) to prevent recurrence of bladder cancer.METHODS: Totally 90 patients treated for superficial bladder cancer patients were randomly divided into A,B,C groups with 30 cases,of which A group underwent intravesical THP treatment,30 mg/f,once a week,were treated 8 times.B group also line THP instillation therapy,and the first 8 weeks of treatment,the same with the A group,and then once a month instead of infusion,30 mg/f,once every 10 months,with a total course of 12 months.C group underwent intravesical instillation of BCG(BCG) therapy,80 mg/f,1 times / week,then gradually reduce the number of treatments,the total course of 12 months.Compared three groups of patients and the recurrence rate of adverse reactions.RESULTS: The patients were followed for two years,including A,B,C three groups of patients 1 year after the recurrence rate was 10.0%(3/30),6.7%(2/30),6.7%(2/30).There was no significant difference(χ2=1.8,P>0.05).Three groups of patients 2 years after the recurrence rate was 16.7%(5/30),13.3%(4/30),9.0%(3/30),in which A group and C group significantly different(χ2=9.2,P<0.05).Adverse reaction rates were 10.0%(3/30),20.0%(6/30),36.7%(11/30).A,B adverse reactions in both groups was significantly less than C group(χ2=11.8,P<0.05).CONCLUSION: THP instillation for preventing recurrence of bladder cancer,short-and long-term efficacy was no different,and its long-term efficacy of BCG was no significant difference in efficacy,but fewer adverse reactions,according to the specific situation of patients with drugs.更多还原